Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2025-09-30 Share Issue/Capital Cha…
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Number of shares and votes in Oncopeptides
Share Issue/Capital Change Classification · 1% confidence The document announces a change in the total number of shares and votes in Oncopeptides AB following a rights issue. This type of disclosure is a standard regulatory requirement regarding capital structure changes and share issuance. Since it specifically details the change in share count and capital resulting from a corporate action (rights issue), it falls under the category of Share Issue/Capital Change.
2025-09-30 English
Oncopeptides’ rights issue oversubscribed to approximately 157 percent
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing the outcome of a rights issue (capital raise) for Oncopeptides AB. It details the subscription results, the number of shares issued, the impact on share capital, and lock-up undertakings. This falls under the category of share issuance and capital changes. While it mentions the rights issue, it is the announcement of the outcome rather than the prospectus itself, and it fits the definition of a share issue/capital change announcement.
2025-09-17 English
Oncopeptides företrädesemission övertecknad till cirka 157 procent
Share Issue/Capital Change Classification · 1% confidence The document is a press release from Oncopeptides AB announcing the final outcome of a rights issue (företrädesemission). It details the subscription levels, the number of shares issued, the impact on share capital, and lock-up commitments. While it discusses capital changes, it is a formal announcement of the results of a completed financing event rather than a prospectus or a standalone regulatory filing for a new share issue. Given the specific nature of the announcement regarding the outcome of a capital raise, it fits best under 'Capital/Financing Update'.
2025-09-17 Swedish
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 1% confidence The document is a formal notification of a change in shareholding (flagging) for Oncopeptides AB, submitted to the Swedish Financial Supervisory Authority (Finansinspektionen). It details the threshold crossing (5%) by Avanza Bank Holding AB. This type of disclosure is a standard regulatory requirement for major shareholders, which falls under the 'Major Shareholding Notification' category.
2025-08-29 Swedish
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 1% confidence The document is a formal notification of a change in shareholding (flagging) for Oncopeptides AB, submitted by Avanza Bank Holding AB. It details the transaction date, the number of shares held before and after the transaction, and the percentage of voting rights, specifically noting that a threshold (5%) has been crossed. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2025-08-28 Swedish
Oncopeptides publishes disclosure document regarding rights issue
Report Publication Announcement Classification · 1% confidence The document is a press release announcing the publication and availability of a disclosure document (prospectus) related to a rights issue. It explicitly states that the disclosure document has been registered and provides links to it. Following the 'Menu vs Meal' rule, this is an announcement of a report rather than the report itself, and it fits the definition of a Report Publication Announcement (RPA).
2025-08-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.